|
ADT Clinical Trials
7 actively recruiting trials across 5 locations
Also known as: Androgen Deprivation Therapy, Androgen deprivation therpay, Hormone Therapy
Pipeline
Phase 2: 3Phase 3: 2Phase 1/2: 2
Top Sponsors
- Canadian Cancer Trials Group2
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1
- Peter Busch Østergren1
- National Cancer Institute (NCI)1
- M.D. Anderson Cancer Center1
Indications
- Cancer7
- Prostate Cancer3
- Prostate Neoplasms1
- Intense Endocrine Therapy1
- Locally Advanced Prostate Cancer1
Other2 trials
Anchorage, Alaska1 trial
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Anchorage Associates in Radiation Medicine
Phase 3
Antioch, California1 trial
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
Kaiser Permanente-Deer Valley Medical Center
Phase 3
Duarte, California1 trial
Bethesda, Maryland1 trial
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
National Institutes of Health Clinical Center
Phase 1/2
Houston, Texas1 trial
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
M D Anderson Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.